Simona Rolla
Orbassano, 10043, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Dynamics of Myelin-Specific T-Cell Repertoires Mirror Disease Activity and Central Nervous System Trafficking in Multiple Sclerosis.
Journal: International journal of molecular sciences
Published: June 17, 2026
Integrative Transcriptomics Uncovers IFN-β Signature and IFITM3 as Putative Molecular Mediator in MS.
Journal: International journal of molecular sciences
Published: February 24, 2026
The Hidden Players in Multiple Sclerosis Nutrition: A Narrative Review on the Influence of Vitamins, Polyphenols, Salt, and Essential Metals on Disease and Gut Microbiota.
Journal: Nutrients
Published: December 05, 2025
Targeting Lifestyle in CNS Inflammatory Demyelinating Diseases: Insights from Diet and Exercise as Potential Disease Modifiers.
Journal: Brain sciences
Published: November 06, 2025
Gut microbiome profiling at multiple sclerosis onset as a potential early prognostic marker of disease course: evidence from an observational cohort study.
Journal: EBioMedicine
Published: June 10, 2025
Lower Multiple Sclerosis Severity Score Is Associated with Higher Adherence to Mediterranean Diet in Subjects with Multiple Sclerosis from Northwestern Italy.
Journal: Nutrients
Published: February 23, 2024
Long-lasting neutralizing antibodies and T cell response after the third dose of mRNA anti-SARS-CoV-2 vaccine in multiple sclerosis.
Journal: Frontiers in immunology
Published: April 14, 2023
Feeding the gut microbiome: impact on multiple sclerosis.
Journal: Frontiers in immunology
Published: February 28, 2023
A new computational workflow to guide personalized drug therapy.
Journal: Journal of biomedical informatics
Published: February 28, 2023
Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies.
Journal: Multiple sclerosis and related disorders
Published: March 01, 2022
Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up.
Journal: Frontiers in immunology
Published: November 19, 2021
Last Updated: 09/26/2026